Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL

Clinical Immunology

Volumn 122, Issue 1, 2007, Pages 28-40

  Martínez Lorenzo, María José ^a   Anel, Alberto ^b   Saez Gutierrez, Berta ^a   Royo Cañas, María ^a   Bosque, Alberto ^b   Alava, María Angeles ^b   Piñeiro, Andrés ^b   Lasierra, Pilar ^a   Asín Ungría, Jaime ^a   Larrad, Luis ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Apoptosis; Human; Rheumatoid arthritis; T lymphocytes; Tolerance

Indexed keywords

CD69 ANTIGEN; DEATH RECEPTOR; FAS ANTIGEN; HLA DR ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CH 11; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; T LYMPHOCYTE;

ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD95; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; JURKAT CELLS; MALE; MIDDLE AGED; PHENOTYPE; SYNOVIAL FLUID; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33845910082     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.07.007     Document Type: Article

References (44)

1. Harris E.D. Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 322 (1990) 1277-1289
2. Pope R.M. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat. Rev., Imunol. 2 (2002) 1-9
3. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 423 (2003) 356-361
4. Nakajima T., Aono H., Hasunuma T., Yamamoto K., Shirai T., Hirohata K., and Nishioka K. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum. 38 (1995) 485-491
5. Kobayashi T., Okamoto K., Kobata T., Hasumuna T., and Nishioka K. Apomodulation as a novel therapeutic concept for the regulation of apoptosis in rheumatoid synoviocytes. Curr. Opin. Rheumatol. 11 (1999) 188-193
6. Firestein G.S., Yeo M., and Zvaifler N.J. Apoptosis in rheumatoid arthritis synovium. J. Clin. Invest. 96 (1995) 1631-1638
7. Cantwell M.J., Hua T., Zvaifler N.J., and Kipps T.J. Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum. 40 (1997) 1644-1652
8. Hashimoto H., Tanaka M., Suda T., Tomita T., Hayashida K., Takeuchi E., Kaneko M., Takano H., Nagata S., and Ochi T. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 41 (1998) 657-662
9. Zhang H., Yang Y., Horton J.L., Samoilova E.B., Judge T.A., Turka L.A., Wilson J.M., and Chen Y. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J. Clin. Invest. 100 (1997) 1951-1957
10. Yao Q., Glorioso J.C., Evans C.H., Robbins P.D., Kovesdi I., Oligino T.J., and Ghivizzani S.C. Adenoviral mediated delivery of FAS ligand to arthritic joints causes extensive apoptosis in the synovial lining. J. Gene Med. 2 (2000) 210-219
11. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 (1996) 12687-12690
12. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., and Goodwin R.G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
13. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., and Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
14. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., and Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
15. Pan G., Ni J., Wei Y.F., Yu G.L., Gentz R., and Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815-818
16. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrizio R., Dodds R.A., Jame I.E., Rosenberg M., Lee J.C., and Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273 (1998) 14363-14367
17. Martínez-Lorenzo M.J., Alava M.A., Gamen S., Kim J.K., Chuntharapai A., Piñeiro A., Naval J., and Anel A. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur. J. Immunol. 28 (1998) 2714-2725
18. Song K., Chen Y., Göke R., Wilmen A., Seidel C., Göke A., Hilliard B., and Chen Y. TRAIL is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191 (2000) 1095-1103
19. Hilliard B., Wilmen A., Seidel C., Liu T.S.T., Göke R., and Chen Y. Roles of TRAIL in experimental autoimmune encephalomyelitis. J. Immunol. 166 (2001) 1314-1319
20. Lamhamedi-Cherradi S.E., Zheng S.J., Maguschak K.A., Peschon J., and Chen Y.H. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat. Immunol. 4 (2003) 255-260
21. Diehl G.E., Yue H.H., Hsieh K., Kuang A.A., Ho M., Morici L.A., Lenz L.L., Cado D., Riley L.W., and Winoto A. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21 (2004) 877-889
22. Bosque A., Pardo J., Martínez-Lorenzo M.J., Iturralde M., Marzo I., Piñeiro A., Alava M.A., Naval J., and Anel A. Down-regulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL and c-FLIP, Bim or Bcl-x isoform expression. J. Leukocyte Biol. 77 (2005) 568-578
23. + T cell blasts to regulation by APO2L/TRAIL. Eur. J. Immunol. 35 (2005) 1812-1821
24. Tsokos G.C., and Tsokos M. The TRAIL to arthritis. J. Clin. Invest. 112 (2003) 1315-1317
25. Liu Z., Xu H., Hsu H.C., Tousson A., Yang P.A., Wu Q., Liu C., Yu S., Zhang H.G., and Mountz J.D. CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J. Clin. Invest. 112 (2003) 1332-1341
26. Yao Q., Wang S., Gambotto A., Glorioso J.C., Evans C.H., Robbins P.D., Ghivizzani S.C., and Oligino T.J. Intra-articular adenoviral-mediated gene transfer of TRAIL induces apoptosis of arthritic rabbit synovium. Gene Ther. 10 (2003) 1055-1060
27. Monleón I., Martínez-Lorenzo M.J., Monteagudo L., Lasierra P., Taulés M., Iturralde M., Piñeiro A., Larrad L., Alava M.A., Naval J., and Anel A. Differential secretion of Fas ligand- or APO2 ligand/TRAIL-carrying microvesicles during activation-induced death of human T cells. J. Immunol. 167 (2001) 6736-6744
28. Martínez-Lorenzo M.J., Anel A., Gamen S., Monleón I., Lasierra P., Larrad L., Piñeiro A., Alava M.A., and Naval J. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J. Immunol. 163 (1999) 1274-1281
29. Hochberg M.C., Chang R.W., Dwosh I., Lindsey S., Pincus T., and Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 35 (1992) 498-502
30. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., Hillan K., Totpal K., DeForge L., and Ashkenazi A. Differential hepatocyte toxicity of recombinant APO2L/TRAIL versions. Nat. Med. 7 (2001) 383-385
31. Martínez-Lorenzo M.J., Alava M.A., Anel A., Piñeiro A., and Naval J. Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Immunology 89 (1996) 511-517
32. Martínez-Lorenzo M.J., Anel A., Alava M.A., Piñeiro A., Naval J., Lasierra P., and Larrad L. The human melanoma cell line MelJuso secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp. Cell Res. 295 (2004) 315-329
33. Peter M.E., Kischkel F.C., Scheuerpflug C.G., Medema J.P., Debatin K.M., and Krammer P.H. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signalling complex. Eur. J. Immunol. 27 (1997) 1207-1212
34. Miranda-Carús M.E., Balsa A., Benito-Miguel M., Pérez de Ayala C., and Martín-Mola E. IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. J. Immunol. 173 (2004) 1463-1476
35. Renno T., Attinger A., Locatelli S., Bakker T., Vacheron S., and MacDonald H.R. Apoptosis of superantigen-activated T cells occurs preferentially after a discrete number of cell divisions in vivo. J. Immunol. 162 (1999) 6312-6315
36. Zhang J., Bárdos T., Mikecz K., Finnegan A., and Glant T.T. Impaired Fas signaling pathway is involved in defective T cell apoptosis in autoimmune murine arthritis. J. Immunol. 166 (2001) 4981-4986
37. Miranda-Carús M.E., Balsa A., Benito-Miguel M., Pérez De Ayala C., and Martín-Mola E. Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active. Arthritis Rheum. 50 (2004) 2786-2793
38. Park Y.W., Ji J.D., Lee J.S., Ryang D.W., and Yoo D.H. Actinomycin D renders cultured synovial fibroblasts susceptible to TRAIL-induced apoptosis. Scand. J. Rheumatol. 32 (2003) 356-363
39. Mauri C., Chu C.Q., Woodrow D., Mori L., and Londei M. Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody. J. Immunol. 159 (1997) 5032-5041
40. Taneja V., Taneja N., Paisansinsup T., Behrens M., Griffiths M., Luthra H., and David C.S. CD4 and CD8 T cells in susceptibility/protection to collagen-induced arthritis in HLA-DQ8-transgenic mice: implications for rheumatoid arthritis. J. Immunol. 168 (2002) 5867-5875
41. Kang Y.M., Zhang X., Wagner U.G., Yang H., Beckenbaugh R.D., Kurtin P.J., Goronzy J.J., and Weyand C.M. CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J. Exp. Med. 195 (2002) 1325-1336
42. Ronday H.K., van der Laan W.H., Tak P.P., de Roos J.A.D.M., Bank R.A., TeKoppele J.M., Froelich C.J., Hack C.E., Hogendoorn P.C.W., Breedveld F.C., and Verheijen J.H. Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis. Rheumatology 40 (2001) 55-61
43. + cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann. Rheum. Dis. 63 (2004) 483-488
44. Yao Q., Seol D.W., Mi Z., and Robbins P.D. Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis. Arthritis Res. Ther. 8 (2005) R16